Phenomics Australia. (2023). High throughput screening to identify new therapeutic strategies for mucinous ovarian cancer patients. Phenomics Australia.
url :
https://doi.org/10.82509/0rjn-2b18
Phenomics Australia. (2023). Development of iPSC models for ASO screening for TRAPPC4 neurodevelopmental disorder. Phenomics Australia.
url :
https://doi.org/10.82509/52qh-h634
Phenomics Australia. (2023). Generation of Oral Carcinoma Patient-Derived Organoids for Personalised Cancer Research. Phenomics Australia.
url :
https://doi.org/10.82509/megh-9025
Phenomics Australia. (2023). Personalised treatment strategies for patients with early-onset metastatic colorectal cancer. Phenomics Australia.
url :
https://doi.org/10.82509/2b6r-gx60
Phenomics Australia. (2023). Methodology development for high-throughput compound screeing of primary human immune cell cytotoxicity in 3D. Phenomics Australia.
url :
https://doi.org/10.82509/n1xy-vk83
Phenomics Australia. (2023). Development of human GPCR knock-in mice for assessment of therapeutic antibodies. Phenomics Australia.
url :
https://doi.org/10.82509/sfzj-8a72
Phenomics Australia. (2023). Establishing a targeted treatment strategy using epigenetic reprogramming against adverse EMT-induced tumour plasticity in head and neck (oral) squamous cell carcinoma. Phenomics Australia.
url :
https://doi.org/10.82509/9603-1820
Phenomics Australia. (2023). Developing a human induced pluripotent stem cell reporter line for heart valve disease modelling. Phenomics Australia.
url :
https://doi.org/10.82509/wbza-7b96
Phenomics Australia. (2023). Generation of mouse models of inherited heart failure to test the efficacy of novel stem cell based therapies. Phenomics Australia.
url :
https://doi.org/10.82509/tbn7-6d23